Related Experiment Video
Updated: Nov 30, 2025

Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research
Published on: November 3, 2023
Aminophylline for improving acute kidney injury in pediatric patients: A systematic review and meta-analysis
Saad Alsaadoun1, Faisal Rustom2, Hanan Abu Hassan3
1Department of Pediatric, Division of Pediatric Nephrology, Security Forces Hospital, Riyadh 13225, Saudi Arabia.
Insights
Aminophylline may help reduce serum creatinine levels in pediatric patients with acute kidney injury (AKI). However, it does not significantly impact urine output, AKI incidence, or mortality rates in children.
Area of Science:
- Pediatric Nephrology
- Critical Care Medicine
- Pharmacology
Background:
- Acute kidney injury (AKI) is a significant contributor to morbidity and mortality in children.
- The role of aminophylline in preventing or treating pediatric AKI remains unclear.
- This meta-analysis investigates the efficacy of aminophylline in pediatric AKI cases.
Purpose of the Study:
- To assess the effectiveness of aminophylline in pediatric patients diagnosed with AKI.
- To determine if aminophylline administration impacts key renal function markers and patient outcomes.
- To provide evidence for clinical decision-making regarding aminophylline use in pediatric AKI.
Main Methods:
- A systematic literature search was conducted across six major databases (PubMed, EMBASE, Scopus, Cochrane Library, Google Scholar) from January 1995 to May 2019.
- Data from seven identified studies involving aminophylline use in children with AKI were analyzed.
- Risk ratios and standard mean differences were calculated using a random effects model for meta-analysis.
Main Results:
- Single-arm studies showed no significant changes in serum creatinine clearance, urine output, or blood urea nitrogen levels post-aminophylline administration.
- However, double-arm studies revealed that aminophylline significantly reduced serum creatinine levels compared to control groups (mean diff = -34).
- No statistically significant effects were observed for aminophylline on urine output, AKI incidence, or mortality rates.
Conclusions:
- Aminophylline administration in pediatric AKI patients appears to lower serum creatinine levels.
- The treatment did not demonstrate significant adverse effects or impact on AKI incidence, urine output, or mortality.
- Further large-scale, well-designed randomized controlled trials are necessary to confirm these findings and explore long-term effects.
Objectives:
Acute kidney injury (AKI) is a major cause of morbidity and mortality. Whether aminophylline administration can prevent or treat AKI among pediatric patients are not clear. This meta-analysis aimed to assess the efficacy and effectiveness of aminophylline for pediatric AKI.
Methods:
We carried out a systematic search of six databases: PubMed, EMBASE/Excerpta Medica, Scopus, Cochrane library, and Google Scholar from January 1995 up till May 2019. Summary measures of risk ratios and standard mean difference were calculated using the random effects model.
Results:
We identified seven papers containing data on aminophylline use in children with AKI. Meta-analysis of single-arm studies indicated no statistically significant difference in mean rate of serum creatinine clearance (-0.39 [-0.80-1.58], P = 0.52), mean urine output (1.99 [-1.43-5.42]; P = 0.25), or mean blood urea nitrogen levels (0.83 [-1.86-3.03], P = 0.54) before and after aminophylline administration. However, among double-arm studies, aminophylline administration in the intervention arm significantly reduced the serum creatinine level as compared to control arm (mean diff = -34 [-55.18--12.83]; P = 0.002). Mean urine output (-112.68 [-27.43-48.9], P = 0.17), incidence of AKI (RR = 1.05 [0.80-1.37], P = 0.72), and mortality rates (RR = 0.79 [0.42-1.47], P = 0.45) were found to be statistically insignificant.
Conclusions:
Aminophylline administration in children with AKI reduces serum creatinine level without significant adverse effects or effect on the incidence of AKI, urine output, or mortality. Further, large-scale well-planned randomized controlled trials are needed to evaluate its use and its potential long-term effects.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury I: Introduction
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Acute Kidney Injury VI: Nursing Management

